AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXR
  4. [Form 4] Daxor Corporation Insider Trading Activity

[Form 4] Daxor Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Daxor 鈥� DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29. The award is contingent on SEC approval of an amendment to the company鈥檚 2020 Incentive Compensation Plan.

The options vest in three tranches鈥�833 on 24 Jun 2025, 883 on 24 Jun 2026 and 834 on 24 Jun 2027鈥攁nd expire on 24 Jun 2030. No common shares were bought or sold, and beneficial ownership remains solely derivative. The filing represents routine equity compensation rather than an open-market transaction.

Daxor 鈥� DXR ha depositato un Modulo 4 segnalando che il direttore Edward Feuer ha ricevuto 2.500 stock option il 24 giugno 2025, con un prezzo di esercizio di 9,29 $. L鈥檃ssegnazione 猫 subordinata all鈥檃pprovazione da parte della SEC di una modifica al Piano di Incentivazione 2020 della societ脿.

Le opzioni maturano in tre tranche: 833 il 24 giugno 2025, 883 il 24 giugno 2026 e 834 il 24 giugno 2027, e scadono il 24 giugno 2030. Non sono state acquistate o vendute azioni ordinarie e la propriet脿 effettiva rimane esclusivamente derivata. La comunicazione rappresenta una normale compensazione azionaria e non una transazione di mercato aperto.

Daxor 鈥� DXR present贸 un Formulario 4 informando que el director Edward Feuer 谤别肠颈产颈贸 2.500 opciones sobre acciones el 24 de junio de 2025, con un precio de ejercicio de 9,29 $. La concesi贸n est谩 condicionada a la aprobaci贸n de la SEC de una enmienda al Plan de Compensaci贸n Incentivada 2020 de la empresa.

Las opciones se conceden en tres tramos: 833 el 24 de junio de 2025, 883 el 24 de junio de 2026 y 834 el 24 de junio de 2027, y expiran el 24 de junio de 2030. No se compraron ni vendieron acciones comunes, y la propiedad beneficiaria sigue siendo 煤nicamente derivada. La presentaci贸n representa una compensaci贸n de acciones rutinaria, no una transacci贸n en el mercado abierto.

Daxor 鈥� DXR電� 鞚挫偓 Edward Feuer臧� 2025雲� 6鞗� 24鞚检棎 2,500欤� 鞀ろ啞 鞓奠厴鞚� 攵�鞐皼鞎橃潓鞚� 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 頄夓偓臧�瓴╈潃 $9.29鞛呺媹雼�. 鞚� 靾橃棳電� 須岇偓鞚� 2020雲� 鞚胳劶韹半笇 氤挫儊 瓿勴殟 靾橃爼鞎堨棎 雽�頃� SEC 鞀轨澑鞐� 霐半澕 臁瓣贝攵�鞛呺媹雼�.

鞓奠厴鞚� 靹� 氩堨棎 瓯胳硱 氩犾姢韺呺悩氅�, 2025雲� 6鞗� 24鞚检棎 833欤�, 2026雲� 6鞗� 24鞚检棎 883欤�, 2027雲� 6鞗� 24鞚检棎 834欤缄皜 氩犾姢韺呺悩瓿�, 2030雲� 6鞗� 24鞚检棎 毵岆霅╇媹雼�. 氤错喌欤茧姅 毵るГ霅橃 鞎婌晿鞙茧┌, 鞁れ 靻岇湢甓岇潃 韺岇儩霅� 靸來儨搿� 鞙犾霅╇媹雼�. 鞚措矆 鞝滌稖鞚� 瓿店皽 鞁滌灔 瓯半灅臧� 鞎勲媽 鞚检儊鞝侅澑 欤检嫕 氤挫儊鞛呺媹雼�.

Daxor 鈥� DXR a d茅pos茅 un formulaire 4 signalant que le directeur Edward Feuer s鈥檈st vu attribuer 2 500 options d鈥檃chat d鈥檃ctions le 24 juin 2025, 脿 un prix d鈥檈xercice de 9,29 $. Cette attribution est soumise 脿 l鈥檃pprobation par la SEC d鈥檜n amendement au Plan de r茅mun茅ration incitative 2020 de la soci茅t茅.

Les options sont acquises en trois tranches : 833 le 24 juin 2025, 883 le 24 juin 2026 et 834 le 24 juin 2027, et expirent le 24 juin 2030. Aucune action ordinaire n鈥檃 茅t茅 achet茅e ou vendue, et la propri茅t茅 b茅n茅ficiaire reste uniquement d茅riv茅e. Ce d茅p么t repr茅sente une r茅mun茅ration en actions de routine, et non une transaction sur le march茅 ouvert.

Daxor 鈥� DXR reichte ein Formular 4 ein, das berichtet, dass der Direktor Edward Feuer am 24. Juni 2025 2.500 Aktienoptionen zu einem Aus眉bungspreis von 9,29 $ erhalten hat. Die Zuteilung steht unter dem Vorbehalt der Genehmigung durch die SEC einer 脛nderung des Incentive-Verg眉tungsplans 2020 des Unternehmens.

Die Optionen werden in drei Tranchen f盲llig 鈥� 833 am 24. Juni 2025, 883 am 24. Juni 2026 und 834 am 24. Juni 2027 鈥� und verfallen am 24. Juni 2030. Es wurden keine Stammaktien gekauft oder verkauft, und das wirtschaftliche Eigentum bleibt ausschlie脽lich derivativ. Die Meldung stellt eine routinem盲脽ige Aktienverg眉tung dar und keine Transaktion am offenen Markt.

Positive
  • None.
Negative
  • None.

Daxor 鈥� DXR ha depositato un Modulo 4 segnalando che il direttore Edward Feuer ha ricevuto 2.500 stock option il 24 giugno 2025, con un prezzo di esercizio di 9,29 $. L鈥檃ssegnazione 猫 subordinata all鈥檃pprovazione da parte della SEC di una modifica al Piano di Incentivazione 2020 della societ脿.

Le opzioni maturano in tre tranche: 833 il 24 giugno 2025, 883 il 24 giugno 2026 e 834 il 24 giugno 2027, e scadono il 24 giugno 2030. Non sono state acquistate o vendute azioni ordinarie e la propriet脿 effettiva rimane esclusivamente derivata. La comunicazione rappresenta una normale compensazione azionaria e non una transazione di mercato aperto.

Daxor 鈥� DXR present贸 un Formulario 4 informando que el director Edward Feuer 谤别肠颈产颈贸 2.500 opciones sobre acciones el 24 de junio de 2025, con un precio de ejercicio de 9,29 $. La concesi贸n est谩 condicionada a la aprobaci贸n de la SEC de una enmienda al Plan de Compensaci贸n Incentivada 2020 de la empresa.

Las opciones se conceden en tres tramos: 833 el 24 de junio de 2025, 883 el 24 de junio de 2026 y 834 el 24 de junio de 2027, y expiran el 24 de junio de 2030. No se compraron ni vendieron acciones comunes, y la propiedad beneficiaria sigue siendo 煤nicamente derivada. La presentaci贸n representa una compensaci贸n de acciones rutinaria, no una transacci贸n en el mercado abierto.

Daxor 鈥� DXR電� 鞚挫偓 Edward Feuer臧� 2025雲� 6鞗� 24鞚检棎 2,500欤� 鞀ろ啞 鞓奠厴鞚� 攵�鞐皼鞎橃潓鞚� 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 頄夓偓臧�瓴╈潃 $9.29鞛呺媹雼�. 鞚� 靾橃棳電� 須岇偓鞚� 2020雲� 鞚胳劶韹半笇 氤挫儊 瓿勴殟 靾橃爼鞎堨棎 雽�頃� SEC 鞀轨澑鞐� 霐半澕 臁瓣贝攵�鞛呺媹雼�.

鞓奠厴鞚� 靹� 氩堨棎 瓯胳硱 氩犾姢韺呺悩氅�, 2025雲� 6鞗� 24鞚检棎 833欤�, 2026雲� 6鞗� 24鞚检棎 883欤�, 2027雲� 6鞗� 24鞚检棎 834欤缄皜 氩犾姢韺呺悩瓿�, 2030雲� 6鞗� 24鞚检棎 毵岆霅╇媹雼�. 氤错喌欤茧姅 毵るГ霅橃 鞎婌晿鞙茧┌, 鞁れ 靻岇湢甓岇潃 韺岇儩霅� 靸來儨搿� 鞙犾霅╇媹雼�. 鞚措矆 鞝滌稖鞚� 瓿店皽 鞁滌灔 瓯半灅臧� 鞎勲媽 鞚检儊鞝侅澑 欤检嫕 氤挫儊鞛呺媹雼�.

Daxor 鈥� DXR a d茅pos茅 un formulaire 4 signalant que le directeur Edward Feuer s鈥檈st vu attribuer 2 500 options d鈥檃chat d鈥檃ctions le 24 juin 2025, 脿 un prix d鈥檈xercice de 9,29 $. Cette attribution est soumise 脿 l鈥檃pprobation par la SEC d鈥檜n amendement au Plan de r茅mun茅ration incitative 2020 de la soci茅t茅.

Les options sont acquises en trois tranches : 833 le 24 juin 2025, 883 le 24 juin 2026 et 834 le 24 juin 2027, et expirent le 24 juin 2030. Aucune action ordinaire n鈥檃 茅t茅 achet茅e ou vendue, et la propri茅t茅 b茅n茅ficiaire reste uniquement d茅riv茅e. Ce d茅p么t repr茅sente une r茅mun茅ration en actions de routine, et non une transaction sur le march茅 ouvert.

Daxor 鈥� DXR reichte ein Formular 4 ein, das berichtet, dass der Direktor Edward Feuer am 24. Juni 2025 2.500 Aktienoptionen zu einem Aus眉bungspreis von 9,29 $ erhalten hat. Die Zuteilung steht unter dem Vorbehalt der Genehmigung durch die SEC einer 脛nderung des Incentive-Verg眉tungsplans 2020 des Unternehmens.

Die Optionen werden in drei Tranchen f盲llig 鈥� 833 am 24. Juni 2025, 883 am 24. Juni 2026 und 834 am 24. Juni 2027 鈥� und verfallen am 24. Juni 2030. Es wurden keine Stammaktien gekauft oder verkauft, und das wirtschaftliche Eigentum bleibt ausschlie脽lich derivativ. Die Meldung stellt eine routinem盲脽ige Aktienverg眉tung dar und keine Transaktion am offenen Markt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feuer Edward
(Last) (First) (Middle)
109 MECO LANE
(Street)
OAK RIDGE, TN 37830
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) $9.29 06/24/2025(1) A 2,500 (2) 06/24/2030 COMMON STOCK 2,500 $0 2,500 D
Explanation of Responses:
1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
/s/ Edward Feuer 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider transaction did DXR report on 29 June 2025?

Director Edward Feuer received 2,500 stock options at a $9.29 exercise price, disclosed in the Form 4.

When do the newly awarded DXR options vest?

The options vest in three installments: 833 on 6/24/2025, 883 on 6/24/2026, and 834 on 6/24/2027.

Are there any conditions attached to Feuer鈥檚 DXR option grant?

Yes. The grant is contingent on SEC approval to amend the Daxor 2020 Incentive Compensation Plan.

What is the expiration date of the granted DXR options?

The options expire on 24 June 2030 if not exercised earlier.
Stock DXR logo
DAXOR CORP

NASDAQ:DXR

DXR Rankings

#7933 Ranked by Market Cap
N/A Ranked by Dividends
#108 Top Gainer

DXR Latest News

Aug 12, 2025
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Aug 7, 2025
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Jul 22, 2025
Daxor鈥檚 Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
May 14, 2025
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
May 13, 2025
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

DXR Latest SEC Filings

Aug 7, 2025
[8-K] Daxor Corporation Reports Material Event
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 1, 2025
[8-K] Daxor Corporation Reports Material Event
Jun 26, 2025
[Form 4] Daxor Corporation Insider Trading Activity

DXR Stock Data

49.62M
2.14M
56.9%
1.96%
0.22%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
NEW YORK